Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Geoff Martha has taken over as chief executive of Medtronic in less
than ideal circumstances. The world’s largest medtech has been hit hard
by patients delaying elective surgical procedures so as to stay out of
hospital while the Covid-19 pandemic rages on. Last week Medtronic said
its weekly US sales for the past few weeks had declined around 60% year
over year.
This is bad enough. But the group also said it would pause enrolment into its clinical trials currently recruiting patients, “to allow hospital clinical resources to focus on fighting Covid-19”. This could have a longer-term effect, delaying the launch of some of its important new products, most notably Intrepid, its transcatheter mitral valve.
The pivotal US trial of Intrepid is – or was – still in its recruitment phase. The Apollo study aimed to sign up 1,600 patients with moderate or severe symptomatic mitral regurgitation and compare the minimally invasive valve with surgical valve implantation. Results were expected in the third quarter of 2021.
This is now in doubt, which is a concern since Abbott Laboratories is hot on Medtronic’s heels. Abbott’s US pivotal of its own mitral valve, Tendyne, is scheduled to conclude in spring 2022, and the group has said nothing about halting recruitment into this or any other study. If Abbott can keep its trial on track, Medtronic’s first mover advantage could shrink or disappear entirely.
Another transcatheter valve trial will also be affected by the trial halt. A small study
of the Harmony pulmonary valve had been expected to read out in the
coming months but according to clinicaltrials.gov is still recruiting
patients. This could slow Medtronic’s plans to add a second pulmonary
valve to its offering – its Melody device has been on sale in Europe
since 2006 and in the US since 2010.
Lastly, a trial investigating the application of Medtronic’s Visualase laser ablation system to temporal lobe epilepsy could be delayed beyond 2022. The device is used under MRI guidance, and is approved as a surgical device for many different applications; this trial specifically examines its use in patients with drug-resistant epilepsy, a significant unmet need.
Of these trials, Apollo is by far the most important to Medtronic’s ambitions. The table below shows EvaluateMedTech’s consensus sales forecasts for the top five medtechs in 2026, and while Medtronic is still forecast to be at the top Abbott is set to climb the rankings. If Apollo is halted for six months or so and Summit continues as scheduled, the valves could be launched in the US at roughly the same time, giving Abbott a better chance than it might otherwise have had.
Medtronic will report its full-year results for fiscal 2020 next
month, and has already cautioned that it expects further pressure from
the pandemic, stating that its results will reflect an additional month
of impact compared with many other companies that operate on a
calendar-based fiscal year.
It also set out where it expects to see the most dramatic effects. The products used in more urgent procedures such as pacemakers and its Solitaire device, used to treat ischaemic stroke, are likely to continue selling; its cryoablation catheters, used in atrial fibrillation, and attempts to move diabetes patients onto its insulin pumps, might be less resilient.
https://www.evaluate.com/vantage/articles/news/corporate-strategy/crucial-trials-medtronic-has-had-pause
This is bad enough. But the group also said it would pause enrolment into its clinical trials currently recruiting patients, “to allow hospital clinical resources to focus on fighting Covid-19”. This could have a longer-term effect, delaying the launch of some of its important new products, most notably Intrepid, its transcatheter mitral valve.
The pivotal US trial of Intrepid is – or was – still in its recruitment phase. The Apollo study aimed to sign up 1,600 patients with moderate or severe symptomatic mitral regurgitation and compare the minimally invasive valve with surgical valve implantation. Results were expected in the third quarter of 2021.
This is now in doubt, which is a concern since Abbott Laboratories is hot on Medtronic’s heels. Abbott’s US pivotal of its own mitral valve, Tendyne, is scheduled to conclude in spring 2022, and the group has said nothing about halting recruitment into this or any other study. If Abbott can keep its trial on track, Medtronic’s first mover advantage could shrink or disappear entirely.
| The mitral race: Medtronic and Abbott’s US pivotal studies | |||||
|---|---|---|---|---|---|
| Company | Device | Trial name | N | PCD | Trial ID |
| Abbott Laboratories | Tendyne | Summit | 958 | Jun 2022 | NCT03433274 |
| Medtronic | Intrepid | Apollo | 1600 | Oct 2021 | NCT03242642 |
| PCD = primary completion date. Source: Clinicaltrials.gov & company communications. | |||||
Lastly, a trial investigating the application of Medtronic’s Visualase laser ablation system to temporal lobe epilepsy could be delayed beyond 2022. The device is used under MRI guidance, and is approved as a surgical device for many different applications; this trial specifically examines its use in patients with drug-resistant epilepsy, a significant unmet need.
Of these trials, Apollo is by far the most important to Medtronic’s ambitions. The table below shows EvaluateMedTech’s consensus sales forecasts for the top five medtechs in 2026, and while Medtronic is still forecast to be at the top Abbott is set to climb the rankings. If Apollo is halted for six months or so and Summit continues as scheduled, the valves could be launched in the US at roughly the same time, giving Abbott a better chance than it might otherwise have had.
| Top 5 medtech companies in 2026 | |||||
|---|---|---|---|---|---|
| Total medtech sales 2019 ($bn) | Total medtech sales 2026e ($bn) | CAGR | Market share 2019 | Market share 2026e | |
| Medtronic | 30.8 | 42.4 | +5% | 6.8% | 5.9% |
| Johnson & Johnson | 26.0 | 33.1 | +4% | 5.7% | 4.6% |
| Abbott Laboratories | 19.9 | 30.7 | +6% | 4.4% | 4.3% |
| Stryker | 14.9 | 22.1 | +6% | 3.3% | 3.1% |
| Siemens Healthineers | 16.3 | 22.1 | +4% | 3.6% | 3.1% |
| Source: EvaluateMedTech. | |||||
It also set out where it expects to see the most dramatic effects. The products used in more urgent procedures such as pacemakers and its Solitaire device, used to treat ischaemic stroke, are likely to continue selling; its cryoablation catheters, used in atrial fibrillation, and attempts to move diabetes patients onto its insulin pumps, might be less resilient.
| Medtronic’s therapies – urgent vs elective | ||
|---|---|---|
| More urgent | Moderately elective | More elective |
| Cardiac and vascular | ||
| Pacing | Implanted defibrillators | Atrial fibrillation |
| Aortic | TAVR/structural heart | Endovenous |
| Coronary | Peripheral | Diagnostics |
| Cardiac surgery | ||
| Minimally invasive therapies | ||
| Surgery: appendectomy, bowel obstruction, trauma | Surgery: CABG, oncology | Surgery: bariatric, hysterectomy, hernia |
| Respiratory and patient monitoring | Gastrointestinal | |
| Renal Care | ||
| Restorative therapies | ||
| Spine trauma | Brain modulation | Other spine |
| Neurovascular: ischaemic stroke | Neurovascular: haemorrhagic stroke | Pain therapies |
| Pelvic health | ||
| Ear, nose and throat | ||
| Diabetes | ||
| Diabetes supplies | New insulin pump starts | |
| TAVR = transcatheter aortic valve replacement. CABG = coronary artery bypass graft.Source: adapted from Medtronic release. | ||
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.